Quasi - Ligand Based Design
The protein structure is not known for the majority of targets, therefore sets of ligands known to interact with the target can be explored in virtual site models generated using Quasi.

Quasi is De Novo’s technology for the generation of pharmacophores and pharmacophore-based virtual screening. It produces molecular overlays of target ligands by superimposing conformers on common pharmacophoric features. The resulting extended pharmacophores may be used to prioritise compounds for screening: Quasi can quickly rank large numbers of compounds by their (partial) fit to the pharmacophore. The pharmacophores may also be used as input for de novo design using SkelGen. SkelGen will design novel molecules to fit the shape of the superposed molecules and fulfil the pharmacophoric points, allowing generation of novel scaffolds.

Print this page


 
Recent News
De Novo Agrees Med Chem Synthesis Deal
De Novo Launches Academic Access Programme
De Novo Takes SkelGen to Japan
De Novo Launches ‘Stand-Alone; SkelGen
De Novo signs first academic licence with the University of Hertfordshire
De Novo Pharmaceuticals announces a Drug Discovery Partnership agreement with Achaogen
De Novo Pharmaceuticals Ltd. Announces New Partnering Opportunity in Diabetes
De Novo Pharmaceuticals Ltd. Announces New Therapeutic Focus In the Area Of Metabolic Diseases And Appoints New Scientific Advisory Board.
De Novo Pharmaceuticals Ltd Announces Drug Discovery Collaboration Agreement with Genzyme
De Novo launches Reflex, a major upgrade to its in silico drug design platform